目的 初步建立中成药重复用药评价标准。方法 采用改进德尔菲法,邀请15位专家进行2轮问卷调查,收集整合专家意见,使用 SPSS23.0计算专家的积极系数、权威程度、问卷信度、专家意见集中程度与协调程度,并根据已设定的筛选原则修订该标准。结果 两轮问卷中,专家的积极度分别为100.00%及93.33%,平均权威系数为0.91,问卷信度分别为0.87与0.82。专家的协调系数分别为0.36(P＜0.01)及0.46(P＜0.01)。最终形成涵盖3个一级条目与6个二级条目的评价标准。结论 本实验采用改进德尔菲法,专家积极度及权威性高,评分可信,具有较高的集中度与较好的一致性,初步形成了中成药重复用药的评价标准。
Abstract
OBJECTIVE To establish the criteria in repeated usage of traditional Chinese patent medicines. METHODS Fifteen experts were invited to take a two-rounded questionnaire survey. Experts' positive coefficients, authority coefficient, reliability, concentration degree and coordination degree towards experts' opinions were calculated by SPSS23.0 after integrating the opinions. The criteria were modified based on the prespecified principles. RESULTS In this two-rounded survey, experts' positive coefficients were 100.00% and 93.33%, averaging authority coefficient was 0.91, reliability of two rounds were 0.87 and 0.82. Coordination degree increased from 0.36 (P<0.01) to 0.46 (P<0.01). Three first level index and eighteen second level index were included in this cirteria. CONCLUSION With well response, authority, reliability and coordination, this study could define preliminary evaluation criteria of repeated traditional Chinese patent medicines.
关键词
改进德尔菲法 /
中成药 /
重复用药 /
合理用药 /
处方点评
{{custom_keyword}} /
Key words
modified Delphi method /
traditional Chinese patent medicines /
repeated medication /
rational drug use /
prescription comment
{{custom_keyword}} /
中图分类号：
R951
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WANG Y G, LI H Y, KONG X W, et al. Exploration of the key factors for clinical rational use of Chinese patent medicine based on prescription evaluation [J]. J China Pharm(中国药房), 2014, 25(11):970-969.
[2] JIN R, WANG Y G, XUE C M, et al. The exploration on the creteria and compromise of prescription review of Chinese patent medicines I:the overdose medication [J]. Chin Hosp Pharm J(中国医院药学杂志), 2015, 35(6):473-477.
[3] NHFPC. Management Practices of Hospital Prescription Comment(Trial)[EB/OL]. (2010)[2017-04-11]. http://www.nhfpc.gov.cn/yzygj/s3590/201003/ac4d04a85da5478793761224abc10fd3.shtml.
[4] BMHB. The Guidance of Special Comments on Prescription in Beijing Medical Institutions (Trial)[S].(2012)[2017-04-11]. http://www.moh.gov.cn/zwgkzt/s9968/201212/f76fcb555824429195c131efc24372d2.shtml.
[5] SATCM. Guidance for Clinical Application of Chinese Patent Medicine [EB/OL]. (2010)[2017-04-11]. http://www.satcm.gov.cn/web2010/zhengwugongkai/yizhengguanli/yiyuanguanli/2010-10-11/10176.html.
[6] JAMIESON S. Likert scale:how to (ab)use them[J]. Med Educ, 2005, 38(12):1217-1218.
[7] DONG D, SUN L H. Study of guideline for drug manufacturer on adverse drug reaction reporting and monitoring with Delphi method[J]. Chin J Pharmacov(中国药物警戒), 2013, 10(9):523-526.
[8] WANG C, SI Q. A study of data statistical processing method of Delphi method and its application [J]. J Inner Mongolia Finance Econ Coll (内蒙古财经大学学报), 2011, 9(4):97-101.
[9] SUN J. Theoretical model for compatibility of medicinal property combination of traditional Chinese medicines [D]. Beijing:Beijing University of Chin Med, 2015.
[10] WANG Y Y, ZHANG Q M, ZHANG Z B. The induction of syndrome factor and affecting target [J]. J Shandong Univ TCM(山东中医药大学学报), 2006, 30(1):6-7.
[11] LINSTONE H A,TUROFF M. Delphi:a brief look backward and forward[J]. Technol Forecast Soc,2010, 78(9):1712-1719.
[12] PING W W, TAN H Z. Progress of Delphi and its use in medicine [J]. Chin J Dis Control Prev (中华疾病控制杂志), 2003, 7(3):243-246.
[13] GUO C Y, WANG Y Q, ZHANG M, et al. Thoughts and suggestions on the use of of Chinese patent medicines in pediatrics [J]. Chin Pharm J (中国药学杂志), 2017, 52(4):327-330.
[14] GAO Y. Analysis and exploration of the reasons of drug withdrawal of Chinese traditional patent medicine [J]. Chin Modern Med (中国当代医药), 2012,19(25):177-178,184.
[15] XU Y Q, HU J L. Statistical analysis of the utilization of Chinese medicine in out-patient electro-prescriptions of our hospital [J]. Chin J Drug Abuse Preven (中国药物滥用防治杂志), 2012, 18(3):157-159.
[16] JIN R, WANG Y G, XUE C M, et al. The exploration on the creteria and compromise of prescription review of Chinese patent medicines Ⅱ:repeated medication[J]. Chin Hosp Pharm J(中国医院药学杂志),2015,35(7):565-570.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家中医药管理局科技专项课题(2013ZX03)
{{custom_fund}}
PDF(1085 KB)
